Dividend and Profit Distribution - The company plans to distribute a cash dividend of 8.79 RMB per 10 shares, totaling approximately 52,740,000 RMB, which represents 30% of the net profit attributable to shareholders for 2021[7]. - The total share capital for the dividend calculation is estimated at 60,000,000 shares, subject to adjustment based on the actual share capital on the dividend record date[7]. - The company has not proposed any capital reserve transfer to increase share capital or stock dividends for 2021[7]. - The company has a cash dividend policy that prioritizes cash dividends at a minimum of 80% for mature stages without major capital expenditures, 40% with major expenditures, and 20% for growth stages with major expenditures[198]. - The company must have positive distributable profits and no significant investment plans to qualify for cash dividends, with a minimum annual cash distribution of 10% of the current year's distributable profits[198]. Financial Performance - The company's total revenue for 2021 was approximately ¥351.19 million, representing an 88.18% increase compared to ¥186.62 million in the previous year[32]. - Net profit attributable to shareholders for 2021 was approximately ¥175.78 million, a 105.16% increase from ¥85.68 million in 2020[32]. - The net cash flow from operating activities for 2021 was approximately ¥118.23 million, reflecting a 51.16% increase from ¥78.22 million in the previous year[32]. - The company's total assets at the end of 2021 were approximately ¥1.10 billion, a 22.27% increase from ¥900.61 million at the end of 2020[32]. - The basic earnings per share for 2021 was ¥2.93, a 71.35% increase compared to ¥1.71 in 2020[34]. - The weighted average return on equity for 2021 was 18.47%, a slight decrease of 0.73 percentage points from 19.20% in 2020[34]. - The net profit attributable to shareholders increased by 105.16% year-on-year, while the net profit after deducting non-recurring gains and losses grew by 89.74%[37]. - Basic earnings per share increased by 57.83% year-on-year, with diluted earnings per share rising by 69.49%[37]. - The gross profit margin for the main business was 85.21% during the reporting period[78]. - The company's gross profit margin for 2021 was 85.21%, a decrease of 0.76 percentage points from the previous year[87]. Research and Development - The R&D expenditure as a percentage of total revenue for 2021 was 15.37%, an increase of 1.28 percentage points from 14.09% in 2020[34]. - The company invested a total of 53.97 million yuan in R&D, representing a 105.22% increase year-on-year, with R&D expenses accounting for 15.37% of sales revenue[47]. - The company submitted 17 new patent applications and obtained 12 new authorizations during the year[47]. - The company achieved a total R&D investment of ¥53,968,557.23, representing a 105.22% increase compared to the previous year[65]. - The number of R&D personnel increased to 58, representing 27.9% of the total workforce, up from 18.3% in the previous year[70]. - The company completed the development of 50 new structural derivatives and optimized 21 derivative products during the reporting period[126]. - The company is focusing on the development of innovative polyethylene glycol-modified drugs and medical devices, with ongoing R&D investments[78]. Market and Sales Performance - The company experienced rapid growth in domestic product sales due to increased orders from major clients, contributing to the overall revenue increase[34]. - International product sales also grew rapidly, driven by stable order increases from overseas clients and new product orders from newly developed customers[34]. - Domestic revenue was 165 million yuan, a 79.44% increase, primarily from increased sales of products and technical service fees[100]. - International revenue reached 186 million yuan, up 96.73%, due to stable order growth from overseas clients and new product orders[100]. - The top five customers accounted for 63.66% of total sales, with the largest customer contributing ¥5,655.49 million, or 16.10%[105]. Corporate Governance - The company has established a comprehensive corporate governance system, including rules for the shareholders' meeting, board of directors, and supervisory board, ensuring clear responsibilities and procedures[156]. - The company held a total of 4 shareholder meetings in 2021, including 1 annual meeting and 3 extraordinary meetings, ensuring compliance with legal regulations and protecting minority shareholders' rights[159]. - The board of directors convened 9 meetings in 2021, adhering to legal and regulatory requirements, which enhanced the board's operational standards and decision-making processes[159]. - The company disclosed significant information accurately and timely, maintaining transparency and protecting the interests of minority investors[156]. - The company implemented a strict insider information management system to limit the number of individuals with access to sensitive information[156]. Risks and Challenges - The company faces risks related to market competition and potential declines in gross profit margin due to rising production costs[78]. - The company faced a risk of increased tax rates if it fails to maintain its high-tech enterprise status, which currently allows for a 15% corporate income tax rate[81]. - The company's products are significantly impacted by U.S. trade policies, with 60.34% of sales revenue derived from the U.S. market[83]. Future Outlook and Strategy - The company plans to continue expanding its market presence and enhancing its product offerings through ongoing R&D efforts[34]. - The company aims to enhance its technical innovation capabilities and maintain a leading position in the PEG-derived drug industry by focusing on continuous innovation and exploring new application scenarios[145]. - Over the next three years, the company plans to strengthen its R&D capabilities by increasing investments in advanced equipment, research funding, and human resources to improve market responsiveness[149]. - The company will focus on the production and sales of PEG-derived drugs while providing technical services and preclinical solutions, aiming to accelerate the development of proprietary products[149]. - The company intends to enhance its market presence by increasing marketing investments and optimizing service processes to improve service quality[149].

Financial Performance - In 2021, the company's operating revenue reached ¥351,190,577.05, representing an increase of 88.18% compared to ¥186,622,625.68 in 2020[33]. - The net profit attributable to shareholders was ¥175,780,091.14 in 2021, up 105.16% from ¥85,678,928.62 in 2020[33]. - The net profit after deducting non-recurring gains and losses was ¥157,174,080.41, reflecting an increase of 89.74% compared to ¥82,834,678.71 in 2020[33]. - The net cash flow from operating activities was ¥118,234,668.15, a 51.16% increase from ¥78,220,725.99 in 2020[33]. - As of the end of 2021, the total assets amounted to ¥1,101,185,583.81, a 22.27% increase from ¥900,611,434.81 at the end of 2020[33]. - The net assets attributable to shareholders were ¥1,051,632,483.11, which is a 22.82% increase from ¥856,243,364.98 at the end of 2020[33]. - The basic earnings per share for 2021 were ¥2.93, representing a 71.35% increase from ¥1.71 in 2020[33]. - The comprehensive gross margin for the year was 85.21%, a decrease of 0.76 percentage points from the previous year[88]. - The company's total revenue for the reporting period increased by 88.18% year-on-year, driven by increased orders from domestic and international clients[36]. Research and Development - The R&D investment accounted for 15.37% of operating revenue, an increase of 1.28 percentage points from 14.09% in 2020[33]. - Research and development investment reached 53.97 million yuan, a 105.22% increase year-on-year, accounting for 15.37% of total sales revenue[45]. - The company submitted 17 new patent applications and obtained 12 new authorizations during the year[45]. - The company completed 21 process optimizations and developed 50 new structural derivatives during the reporting period[130]. - The number of R&D personnel increased to 58, representing 27.9% of the total workforce, up from 18.3% in the previous year[71]. - The company has filed 17 new invention patent applications and obtained 12 patents during the reporting period, bringing the total to 45 applications and 87 patents[63]. - The company is developing a PEGylated irinotecan project with a total investment of ¥76,500,000, currently in Phase II clinical trials[70]. - The company has established three core technology platforms to create a complete PEGylation technology ecosystem, targeting small molecule drugs, gene drugs, and medical devices[154]. Corporate Governance - The company has confirmed that all board members attended the board meeting, ensuring governance compliance[6]. - The company has not identified any special arrangements for corporate governance or significant matters affecting its operations[11]. - The governance structure includes a strategic committee, nomination committee, compensation and assessment committee, and audit committee to enhance decision-making[163]. - The company held a total of 4 shareholder meetings in 2021, including 1 annual meeting and 3 extraordinary meetings[162]. - The board of directors convened 9 meetings in 2021, ensuring compliance with legal regulations and internal rules[163]. - The supervisory board conducted 8 meetings in 2021, effectively overseeing the company's operations and financial status[163]. - The company disclosed significant information accurately and timely, maintaining transparency and protecting minority investors' interests[163]. - The company has established a comprehensive governance system to ensure the effective operation of the board and protect shareholder rights[163]. Market and Sales - The company's revenue mainly comes from the sales of PEG materials and related technical services, while self-developed PEG-modified drugs and Class III medical devices are still in preclinical or Phase II clinical research stages, generating no revenue yet[46]. - The company employs a direct sales model for both domestic and international markets, targeting well-known pharmaceutical companies and research institutions[50]. - The company's foreign sales revenue accounted for 52.88% of its main business income, with a foreign exchange loss of 2.14 million yuan reported during the period[86]. - The company's sales to the U.S. accounted for 60.34% of total sales, with potential impacts from U.S. trade protection policies and tariffs[86]. - The company achieved operating revenue of CNY 351.19 million, an increase of 88.18% compared to the same period last year[92]. - Domestic revenue was CNY 165.49 million, a 79.44% increase, primarily due to increased sales from major clients[99]. - International revenue reached CNY 185.70 million, a 96.73% increase, driven by stable order growth from overseas medical device clients[99]. Risks and Challenges - The company has outlined various operational risks and corresponding mitigation measures in the management discussion and analysis section[5]. - The company is exposed to risks related to international operations and potential changes in laws and regulations[79]. - The company faces risks related to the inability to meet customized client demands for polyethylene glycol derivatives[78]. - The company faced risks related to declining gross margins due to rising production costs and market competition[82]. - The company is advancing several innovative polyethylene glycol-modified drugs and medical devices, with ongoing R&D investments expected to impact profits[82]. Investment and Financial Management - The company plans to distribute a cash dividend of 8.79 RMB per 10 shares, totaling approximately 52,740,000 RMB, which represents 30% of the net profit attributable to shareholders for 2021[7]. - The total share capital for the dividend calculation is estimated at 60,000,000 shares, subject to adjustment based on the actual share capital on the dividend record date[7]. - The company reported a net cash outflow from investment activities of CNY 571.46 million, primarily due to significant capital expenditures on fixed and intangible assets[92]. - The company has implemented a cash management strategy using temporarily idle raised funds for financial products[188]. - The company plans to utilize temporarily idle raised funds for cash management, which will not affect the normal implementation of investment projects[196]. Strategic Initiatives - The company aims to enhance its technical innovation capabilities and maintain a leading position in the PEG-derived pharmaceutical industry by focusing on material innovation and exploring new application scenarios[152]. - The company plans to invest in R&D to strengthen its product development and technical service capabilities, with a focus on PEG-derived drugs and their applications in various fields[155]. - The company intends to expand its market presence by enhancing brand exposure and optimizing service processes in the pharmaceutical and medical device sectors[155]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its product portfolio[178].

Financial Performance - The company's revenue for Q3 2021 reached ¥106,086,991, representing a 76.10% increase compared to the same period last year[8]. - Net profit attributable to shareholders for Q3 2021 was ¥61,726,591.95, marking a 117.91% year-over-year growth[8]. - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥52,669,652.81, an increase of 86.61% compared to the same period last year[8]. - For the first three quarters of 2021, the company achieved total operating revenue of RMB 261.82 million, a year-on-year increase of 108.09%[27]. - The net profit attributable to shareholders for the same period was RMB 142 million, representing a year-on-year growth of 153.63%[27]. - The total operating revenue for the current period reached 166,026,268.80, compared to 65,529,345.98 in the previous period, marking an increase of approximately 153%[34]. - Net profit for the current period was 142,364,121.35, up from 56,129,850.29 in the previous period, representing an increase of about 153%[34]. - The total comprehensive income for the current period was 141,434,010.95, compared to 57,387,027.81 in the previous period, showing an increase of approximately 146%[37]. Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥1,033,144,493.96, reflecting a 14.72% increase from the end of the previous year[12]. - As of September 30, 2021, the company's total assets amounted to RMB 1.03 billion, compared to RMB 900.61 million at the end of 2020[28]. - The total liabilities of the company were RMB 42.27 million, a slight decrease from RMB 44.37 million at the end of 2020[31]. - Total assets decreased from 909,497,719.62 to 900,611,434.81, a reduction of 8,886,284.81[42]. - Current liabilities increased from 43,940,050.79 to 41,311,742.98, a decrease of 2,628,307.81[42]. - Non-current liabilities rose significantly from 9,314,303.85 to 3,056,326.85, an increase of 6,257,977.00[42]. - Total liabilities increased from 53,254,354.64 to 44,368,069.83, a decrease of 8,886,284.81[42]. - Total equity remained stable at 856,243,364.98, unchanged from the previous period[42]. Shareholder Information - The total equity attributable to shareholders at the end of Q3 2021 was ¥990,873,504.51, a 15.72% increase from the end of the previous year[12]. - The equity attributable to shareholders of the parent company reached RMB 990.87 million, up from RMB 856.24 million at the end of 2020[31]. - Basic earnings per share for Q3 2021 were ¥1.03, up 80.70% from the same period last year[12]. - Basic earnings per share for the current period were 2.37, compared to 1.20 in the previous period, reflecting an increase of about 97.5%[37]. Research and Development - Research and development expenses for Q3 2021 totaled ¥18,202,600.78, which is a 63.09% increase year-over-year[12]. - Research and development expenses amounted to 36,333,277.16, compared to 20,895,510.09 in the previous period, reflecting an increase of approximately 74%[34]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥119,181,073.19, showing a significant increase of 221.49% compared to the previous year[12]. - Cash flow from operating activities generated a net amount of 119,181,073.19, significantly higher than 37,071,538.81 in the previous period[37]. - The company reported cash inflow from investment activities totaling 1,310,564,638.60, compared to 60,341,260.28 in the previous period, indicating a substantial increase[39]. - The company experienced a net cash decrease of 448,611,239.38 in cash and cash equivalents, contrasting with an increase of 575,431,331.71 in the previous period[39]. Market and Product Development - The company reported a significant increase in product orders and shipment volumes, contributing to the overall revenue growth[17]. - The company's main business revenue grew rapidly, with product sales revenue reaching RMB 231 million, up 106.43% year-on-year[27]. - Domestic sales revenue was RMB 92 million, an increase of 86.95% compared to the same period last year, while foreign sales revenue was RMB 139 million, up 121.69% year-on-year[27]. - The company plans to continue expanding its market presence and developing new products to drive future growth[25].

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 20%[23] - The company's operating revenue for the first half of the year reached ¥155,735,532.15, a year-on-year increase of 137.48% compared to ¥65,578,360.74 in the same period last year[30] - Net profit attributable to shareholders was ¥80,637,529.40, reflecting a significant increase of 190.02% from ¥27,803,832.00 in the previous year[30] - The net cash flow from operating activities increased by 60.44%, amounting to ¥55,348,502.37, compared to ¥34,498,788.76 in the same period last year[30] - Basic earnings per share increased to ¥1.34, a growth of 116.13% compared to ¥0.62 in the same period last year[34] - The comprehensive gross margin improved to 84.69%, up by 3.3 percentage points from the previous year, driven by increased order volume and changes in product structure[35] - The company achieved a total R&D investment of ¥18,130,676.38, representing an 86.25% increase compared to the previous period[59] - The company achieved a revenue of 155.74 million yuan for the period from January 1 to June 30, 2021, representing a growth of 137.48% compared to the same period in 2020[72] - The net profit attributable to shareholders for the same period was CNY 80.64 million, an increase of 190.02% compared to the previous year[80] - The comprehensive gross profit margin for the reporting period was 84.69%, up by 3.3 percentage points from the same period last year[82] Research and Development - Research and development expenses increased by 30% to RMB 50 million, focusing on new technologies and product innovations[23] - Research and development expenses rose to ¥1,800,000, representing an 86.25% increase year-on-year, indicating a strong commitment to innovation[35] - The company has expanded its R&D team to 35 members, with R&D personnel now constituting 20.96% of the total workforce[67] - The company has made significant breakthroughs in low molecular weight PEG and cationic lipids for gene delivery during the reporting period[57] - The company is actively expanding its product line in the PEG derivatives sector, focusing on market potential and technological advancements[69] - The company completed the optimization and improvement of 16 derivative product processes and developed 48 new structural derivatives[71] - The company holds a total of 91 patents, with 16 new patents obtained during the reporting period, including 8 invention patents[58] Market Expansion and Strategy - The company expects a revenue growth forecast of 25% for the second half of 2021, driven by new product launches and market expansion strategies[23] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[23] - A strategic acquisition of a complementary technology firm is under consideration to enhance product offerings and market competitiveness[23] - JianKai Technology has established a direct sales model for both domestic and international markets, targeting well-known pharmaceutical companies and research institutions[47] - The company is actively expanding its market presence and enhancing its brand recognition through participation in exhibitions and targeted marketing strategies[47] Financial Management and Shareholder Policies - The company has no plans for dividend distribution for this reporting period, focusing instead on reinvestment into growth initiatives[23] - The profit distribution policy emphasizes reasonable returns to investors, maintaining continuity and stability, with cash dividends prioritized when conditions allow[191] - The company commits to a cash dividend of no less than 10% of the annual distributable profit and a cumulative distribution of no less than 30% of the average annual distributable profit over the last three years[194] - The company will strictly manage the use of raised funds to ensure they are utilized effectively for their intended purposes[185] - The company will establish a stable profit distribution policy to enhance the investor return mechanism[185] Environmental and Safety Compliance - The company has established a safety and environmental health committee directly under the general manager to oversee daily safety production and environmental protection management[137] - Environmental monitoring includes online detection and regular monitoring by qualified third parties, ensuring compliance with environmental standards[134] - The company has implemented various environmental management systems, including hazardous waste management and environmental hazard rectification[137] - No administrative penalties were imposed on the company during the reporting period for environmental issues[137] Corporate Governance and Shareholder Commitments - The company has committed to a 36-month lock-up period for shares held by major shareholders following the IPO, with an extension of 6 months if the stock price falls below the IPO price for 20 consecutive trading days within the first 6 months[140] - The company will ensure compliance with the Shanghai Stock Exchange's rules regarding shareholding and transfer limitations, including public apologies and corrective actions for any breaches[146] - The company has established a clear framework for managing share transfers and ensuring accountability among its major shareholders and executives[149] - The company will take measures such as disclosing reasons for unfulfilled commitments and compensating investors for losses caused by such failures[199]

Financial Performance - Operating revenue surged by 158.77% to CNY 69,918,824.65 year-on-year[12] - Net profit attributable to shareholders rose by 229.52% to CNY 35,993,273.76 compared to the same period last year[12] - Basic earnings per share increased by 150.00% to CNY 0.60 compared to the same period last year[15] - Total revenue for Q1 2021 reached ¥69,918,824.65, a significant increase from ¥27,019,555.82 in Q1 2020, representing a growth of approximately 159.5%[46] - Net profit for Q1 2021 was ¥35,993,273.76, compared to ¥10,922,899.96 in Q1 2020, marking an increase of about 229.5%[46] - Operating profit for Q1 2021 was ¥41,925,586.26, compared to ¥12,650,445.57 in Q1 2020, indicating an increase of approximately 230.5%[46] - Total comprehensive income for Q1 2021 was ¥35,552,598.07, compared to ¥11,180,337.22 in Q1 2020, reflecting an increase of approximately 218.5%[48] Cash Flow - Net cash flow from operating activities reached CNY 6,243,487.18, a significant recovery from a negative cash flow of CNY -2,082,630.90 in the previous year[12] - Cash flow from operating activities totaled 5,409,702.26 RMB, significantly higher than 1,949,731.18 RMB in the previous year, marking an increase of 177%[51] - Cash inflow from operating activities totaled ¥150,705,302.53 in Q1 2021, compared to ¥30,078,702.51 in Q1 2020[49] - The net cash flow from investing activities was -329,617,861.24 RMB, worsening from -111,943.01 RMB year-over-year[51] Assets and Liabilities - Total assets increased by 6.59% to CNY 959,920,354.30 compared to the end of the previous year[12] - Current assets totaled ¥827,235,566.31, up from ¥785,063,564.10, indicating an increase of about 5.7% year-over-year[36] - Total liabilities amounted to ¥63,475,457.92, up from ¥44,368,069.83, reflecting an increase of about 43%[39] - Shareholders' equity reached ¥896,444,896.38, compared to ¥856,243,364.98, indicating a growth of approximately 4.7%[39] - The company reported a significant increase in contract liabilities, which rose to ¥13,347,437.09 from ¥4,855,882.81, representing an increase of about 175%[39] Shareholder Information - The total number of shareholders at the end of the reporting period was 3,788[16] - The largest shareholder, Xuan Zhao, holds 24.78% of the shares, totaling 14,866,610 shares[16] Research and Development - R&D expenditure as a percentage of operating revenue decreased by 7.76 percentage points to 8.73%[15] - Research and development expenses increased by 37.02% to ¥6,103,116.00, driven by higher labor and outsourcing costs[28] - Research and development expenses in Q1 2021 totaled ¥6,103,116.00, up from ¥4,454,023.05 in Q1 2020, representing a rise of about 37%[46] Government Subsidies - The company reported a government subsidy of CNY 26,147.58 related to its normal business operations[15] Inventory and Receivables - Accounts receivable increased by 84.21% to ¥84,938,751.66, reflecting a rise in operating income[22] - Prepayments surged by 741.57% to ¥21,423,173.15, primarily due to the investment project in medical polyethylene glycol[22] - Inventory increased to ¥26,557,562.66 from ¥23,436,550.08, showing a growth of approximately 9%[36] Capital Structure - The company maintained a stable capital reserve of ¥611,039,649.20, slightly increasing from ¥606,390,715.87[39] - The company has a total of $606.39 million in capital reserves, showcasing robust financial health[61] - Shareholders' equity stood at approximately $721.26 million, reflecting a stable capital structure[61] Other Financial Metrics - The weighted average return on net assets decreased by 0.71 percentage points to 4.12%[12] - The company reported a 243.40% increase in income tax expenses to ¥5,932,312.50, attributed to higher sales revenue and total profit[30] - The company experienced a credit impairment loss of ¥1,750,060.07 in Q1 2021, compared to a loss of ¥364,519.88 in Q1 2020, reflecting a deterioration in credit quality[46]

2020 年年度报告 公司代码：688356 公司简称：键凯科技 JenKem Technology 北京键凯科技股份有限公司 2020 年年度报告 1 / 160 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本 报告第四节"经营情况讨论与分析"。 三、 公司全体董事出席董事会会议。 四、 普华永道中天会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 五、 公司负责人赵宣、主管会计工作负责人韩磊及会计机构负责人（会计主管人员）李春雷声明： 保证年度报告中财务报告的真实、准确、完整。 六、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2020年利润分配预案为：公司拟以实施2020年度分红派息股权登记日的总股本为基数， 向全体股东每10股派发现金红利4.29元（含税），预计派发现金红利总额为25,740,000.00元，占 公司2020年度 ...

2020 年第三季度报告 公司代码：688356 公司简称：键凯科技 北京键凯科技股份有限公司 2020 年第三季度报告 1 / 28 2020 年第三季度报告 一、 重要提示 二、 公司基本情况 11[ 重要事项 四、 附录 目录 2 / 28 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人 XUAN ZHAO、主管会计工作负责人韩磊及会计机构负责人（会计主管人员）何炜 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------|------------------------------|--------------------------------------|------------- ...